CLINICAL TRIALS PROFILE FOR SPIRAPRIL HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for SPIRAPRIL HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00473174 ↗ | Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension | Completed | King Pharmaceuticals is now a wholly owned subsidiary of Pfizer | Phase 4 | 2007-03-01 | This prospective chronotherapy trial will investigate the potential differing efficacy of ramipril in doses from 5 to 10 mg/day when administered, as a monotherapy either upon awakening from nighttime sleep or at bedtime, to diurnally active patients with grade 1 or 2 essential hypertension, who will be evaluated by 48-hour ABPM before and after pharmacologic intervention. The benefits from this trial may be extremely important, taking into account 1. the high prevalence of non-dipping among patients with essential hypertension 2. the need for a proper 24-hour BP control with particular emphasis on the regulation of nighttime resting BP mean 3. the lacking information on the administration-time dependent effects on BP of ramipril, a widely used ACEI in doses of 5-10 mg/day. |
| NCT00473174 ↗ | Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension | Completed | University of Vigo | Phase 4 | 2007-03-01 | This prospective chronotherapy trial will investigate the potential differing efficacy of ramipril in doses from 5 to 10 mg/day when administered, as a monotherapy either upon awakening from nighttime sleep or at bedtime, to diurnally active patients with grade 1 or 2 essential hypertension, who will be evaluated by 48-hour ABPM before and after pharmacologic intervention. The benefits from this trial may be extremely important, taking into account 1. the high prevalence of non-dipping among patients with essential hypertension 2. the need for a proper 24-hour BP control with particular emphasis on the regulation of nighttime resting BP mean 3. the lacking information on the administration-time dependent effects on BP of ramipril, a widely used ACEI in doses of 5-10 mg/day. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SPIRAPRIL HYDROCHLORIDE
Condition Name
Clinical Trial Locations for SPIRAPRIL HYDROCHLORIDE
Clinical Trial Progress for SPIRAPRIL HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for SPIRAPRIL HYDROCHLORIDE
Sponsor Name
